Going Viral: Surgeon, Professor Team in New Approach to Pain Treatment

Invent. Protect. Commercialize.

Going Viral: Surgeon, Professor Team in New Approach to Pain Treatment

Carol Duffy and William Pridgen

UA professor Carol Duffy, left, and Tuscaloosa surgeon William “Skip” Pridgen

A chronic pain condition and numerous gastrointestinal disorders may all be caused by a virus.

That’s a Tuscaloosa-based surgeon’s theory likely headed for a clinical trial early next year and one drawing support from a University of Alabama researcher who studies how viruses replicate.

The theory of Dr. William “Skip” Pridgen, the physician, is now at the core of a start-up company, Innovative Med Concepts, which has already raised most of the capital needed to fund the Phase II clinical trial to test a novel pain-treatment therapy.

Pridgen is the company’s president and managing partner. Dr. Carol Duffy, a UA assistant professor of biological sciences, serves as the company’s chief scientific adviser.

The clinical trial will test the effectiveness of a combination of two drugs in treating fibromyalgia, the chronic pain condition known both as a diagnostic and therapeutic dilemma. The trial, pending FDA approval, will involve 140 fibromyalgia patients at 10 sites around the country.

For more, view the full article at Research Magazine.

Carol Duffy and William Pridgen

UA professor Carol Duffy, left, and Tuscaloosa surgeon William “Skip” Pridgen

A chronic pain condition and numerous gastrointestinal disorders may all be caused by a virus.

That’s a Tuscaloosa-based surgeon’s theory likely headed for a clinical trial early next year and one drawing support from a University of Alabama researcher who studies how viruses replicate.

The theory of Dr. William “Skip” Pridgen, the physician, is now at the core of a start-up company, Innovative Med Concepts, which has already raised most of the capital needed to fund the Phase II clinical trial to test a novel pain-treatment therapy.

Pridgen is the company’s president and managing partner. Dr. Carol Duffy, a UA assistant professor of biological sciences, serves as the company’s chief scientific adviser.

The clinical trial will test the effectiveness of a combination of two drugs in treating fibromyalgia, the chronic pain condition known both as a diagnostic and therapeutic dilemma. The trial, pending FDA approval, will involve 140 fibromyalgia patients at 10 sites around the country.

For more, view the full article at Research Magazine.

About the Author